At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 810 enrolled
Drug / intervention
SER120 750 ng +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double Blind, Placebo Controlled, Multicenter Study to Investigate the Efficacy and Safety of SER120 Nasal Spray Formulation in Patients With Nocturia
In Brief
A Phase 3 clinical trial evaluating SER120 750 ng, SER120 1500 ng, and 1 other intervention for Nocturia. Completed, enrolled 810 participants across 1 site.
Detailed Summary
To investigate the efficacy and safety of SER120 nasal spray formulations in patients with nocturia
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNocturia
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJul 2013
Enrollment StartAug 2013
Primary CompletionApr 2015
TodayJul 2026
First PostedJul 16, 2013
Enrollment StartAug 1, 2013
Primary CompletionApr 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 13.0 years ago
Interventions
SER120 750 ngdrug
SER120 750 ng
SER120 1500 ngdrug
SER120 1500 ng
Placebodrug
Placebo